메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'' 기자의 전체기사

TGE Announces Important Strategic Expansion Initiative

PARIS, NEW YORK and SINGAPORE, July 9, 2025 -- The Generation Essentials Group. (NYSE: TGE) (the "Company" or "TGE"), a global media, entertainment and experiencing company, covering high fashion, arts, lifestyle, cultural, entertainment as well as F&B, today announced its intention to implement a business expansion and acquisition strategy in sectors with strategic adjacency. It may take the form of TGE sponsoring and listing a series of special purpose acquisition companies (each a "SPAC"), which then seeks to conduct various "de-SPAC" business co
- 기자
- 2025-07-09 21:25
竞争加剧，默沙东九价凭4亿全球接种剂次筑牢信任

北京 2025年7月9日 -- 来自新华网的报道： HPV感染是全球重要的公共卫生问题之一，在"加速消除宫颈癌全球战略"及"健康中国战略"全面推进的时代背景下，HPV疫苗成为公共健康体系的重要支柱和重要防线。而高价次HPV疫苗可预防更多病毒亚型，防护更全面，因而备受消费者追捧。截至2025年5月，默沙东九价HPV疫苗在全球累计接种已超4亿剂次，覆盖112个国家和地区。现如今，随着国产九价HPV疫苗进入公众视野，"HPV疫苗怎么选"再次成为热议焦点。相同价次下，如何选择最优HPV疫苗考验着消费者的决策能力。在HPV疫苗这个充满期待的领域里，默沙东凭借超高市场占有率，一直稳居HPV疫苗的领导地位。而在目前上市的九价HPV疫苗中，默沙东的佳达修®9是唯一获批用于预防由7种高危型HPV（16、18、31、33、45、52、58型）引起的宫颈癌的九价疫苗，且凭借男性适应证在中国的获批成为首个且目前唯一获批、可适用于男性及女性接种的九价HPV疫苗。这也标志着中国正式进入了"男女共防HPV共创免疫预防新时代"。作为全球首个九价HPV疫苗的研发者，默沙东的故事或许能为我们提供另一种视角——一款疫苗的价值，不仅在于价格标签，更在于其历经时间检验的守护
- 기자
- 2025-07-09 21:07
NYSE Content advisory: Pre-Market update + Trump announc…

NEW YORK, July 9, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content advisory: Pre-Market update + Trump announces 50% levy on copper imports Kristen Scholer delivers the pre-market update on July 9th President Trump announced 50% levy on copper imports on Tuesday President Trump also hinted at implementing up to a 200% tariff on pharmaceutical imports Investors are awaiting today's Fed Minu
- 기자
- 2025-07-09 20:55
2025渴望就可能•百事校园最强音年度盛典点燃今夏

[ 메디채널 기자 ] 音乐渴望交汇，点燃年轻灵魂厦门 2025年7月9日 -- 百事可乐与腾讯音乐娱乐集团联合出品的"渴望就可能•百事校园最强音年度盛典"近日于福建厦门开唱。百事可乐敏锐洞察音乐是点燃年轻世代渴望的关键触点之一，持续深耕"百事校园最强音"这一跨越十余载的标志性IP，不断激发着年轻世代的情感共鸣。在本次盛典上，百事可乐携手品牌首个人形机器人"百事蓝宝"、百事群星、全国高校新秀及原创音乐人，以"渴望就可能"为核心理念，共同续写音乐文化与渴望精神的接力乐章，呈现出一场跨越代际的渴望对话。品牌 IP深耕，见证渴望传承作为一个敢于持续投资"可能性"的品牌IP，百事校园最强音以"未来音乐人的第一块踏板"为定位。历经十二载不辍耕耘，赛事已建立起从"校园海选"到"原创孵化"的成熟音乐成长体系，持续扶植年轻原创力量，成为中国原创音乐领域至关重要的孵化平台与潜力人才源头。经过数月的激烈角逐与专业评审，来自全国高校的18组新生力量脱颖而出，以充满生命力与创造力的音乐作品，唱响年度总决赛的舞台，点燃青春最纯粹的"
- 기자
- 2025-07-09 20:41
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in To…

PISCATAWAY, N.J., July 9, 2025 -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment platform. This recognition underscores its significant progress in the areas of environment, labor and human rights, ethics, and sustainable procurement. This silver medal places GenScript in the top 15% of all companies assessed by EcoVadis worldwide. In the latest reassessment, GenScript outperforms 85% of co
- 기자
- 2025-07-09 20:32
IASO Bio Receives Orphan Drug Designation from the Ministry o…

[ 메디채널 기자 ] SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received a
- 기자
- 2025-07-09 20:18
/DISREGARD RELEASE: M4Markets/

[ 메디채널 기자 ] We are advised by M4Markets that journalists and other readers should disregard the news release, M4Markets Spotlights the Big Trends: What's Shaping the Markets in 2025, issued 08-Jul-2025 over PR Newswire.
- 기자
- 2025-07-09 20:17
GENAI Summit 2025: Forging a Network of AI Innovators

HONG KONG, July 9, 2025 -- The GENAI Summit Hong Kong is designed to foster collaboration and knowledge-sharing, offering a dynamic platform for attendees to dive into the practical applications of GenAI in industries such as finance, healthcare, marketing, education, and entertainment. With an expected attendance of over 500+ participants and representatives from leading gen AI tech companies, the event promises to be a landmark moment for Hong Kong's growing role as a global GEN AI hub. The summit will feature a packed agenda, including: Keynote Addresses: Visionary leader
- 기자
- 2025-07-09 20:02
维泰瑞隆授予诺华收购其跨脑递送平台的独家选择权并保留推进选定项目的权利

[ 메디채널 기자 ] 马萨诸塞州沃尔瑟姆市 2025年7月9日 -- 维泰瑞隆是一家处于临床阶段的生物科技公司，致力于探索和开发用于治疗衰老相关疾病的变革性疗法。公司今日宣布与诺华达成一项战略协议，授予诺华一项独家选择权，以收购其专有的"脑部递送模组（Brain Delivery Module, BDM）"平台。该平台是一种差异化的血脑屏障穿透技术，旨在提高多种形式药物的脑部递送效率。同时，维泰瑞隆保留使用该平台继续开发选定项目的权利。维泰瑞隆总裁兼首席执行官Dr. Shefali Agarwal表示："此次合作将诺华在全球神经科学领域的专业优势与维泰瑞隆高质量的创新成果相结合，最大限度地释放了我们脑部递送平台的潜在影响力。与此同时，我们将继续利用该平台探索我们感兴趣的治疗性靶点，开发具有脑部渗透性的治疗性药物。这一战略协同将助力维泰瑞隆加速其全球拓展和临床开发进程，进一步强化我们为罹患严重神经系统疾病的患者重新定义治疗可能性的承诺。" 诺华生物医学研究所神经科学全球负责人Robert Baloh博士表示："有效实现治疗性药物穿越血脑屏障仍然是药物研发领域最重要的挑战之一。我们很高兴能与维泰瑞隆达成此项协议，充分挖掘BDM平台的前景。我们将依托自身在神经科学领域的深厚专业知识和能力，为有需求的
- 기자
- 2025-07-09 20:00
Sironax Grants Novartis Exclusive Option to Acquire its Brain De…

WALTHAM, Mass., July 9, 2025 -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under which Sironax will grant Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier (BBB) crossing technology designed to enhance the brain delivery of therapeutics of various modalities. Sironax retains the right to continue developing selected therapeutic assets using the platform. &q
- 기자
- 2025-07-09 20:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-26_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 26일 11시 40분